The cultivation of pea pods spans across various regions and climates with a global production of around 20 million tons. The pea peel wastes, which make up 30–40% of the total weight of the peas, are freely available in large quantities. The biomass used was characterized via ultimate, proximate, and structural analysis obtaining a 20,2 %w of cellulose and 17,4 %w of hemicellulose which via valorization processes can be transformed into platform chemicals. Hydrothermal valorization presents itself as a clean form of treatment of said wastes, ranging from 120 – 180 ºC (LHW) to 180 to 260 ºC (HTC). The use of LHW can lead to the production of sugars (up to 70%w yield) and levulinic acid (4 %w yield) while the use of HTC leads to Formic acid (40 %w) and levulinic acid (4 %w yield). The use of LHW for longer times favors the production of HMF and Furfural. The use of homogeneous catalysts (H2SO4, CH3COOH, KOH and NaHCO3) was implemented and their selectivity described. Solid fractions of LHW and HTC were characterized via FTIR and elemental analysis and the change in their structure described as they shift from biomass to biochar. Optimal conditions for each platform chemical were reported for best utilization of the peapod waste.

Understanding the evolution patterns in patients diagnosed with acute myeloid leukemia (AML) after therapy is relevant due to the dismal outcome still present in refractory or relapsed AML patients. We performed a retrospective, single-center study to evaluate the mutation profile in paired samples obtained at the time of diagnosis and at the onset of progressive or refractory disease in patients diagnosed with AML through a commercial next-generation sequencing (NGS) panel. In total, 62 patients were analyzed. Of these, 28 patients received ICT, and 34 patients underwent low-intensity treatments. In LIT patients, there were emergent mutations at progressive disease in a 64% (22/34) of the patients. Emergent mutations in the RAS-MAPK signaling pathway were observed in 35.9% (12/34) , corresponding to 54.5% of all patients with emergent mutations (12/22). These were found in 12/22 patients that received venetoclax in combination with hypomethylating agents. Six presented mutations in genes related to the RAS-MAPK pathway. Emerging mutations are frequently observed at progressive AML disease after therapy. In patients treated with LIT, mutations in RAS-MAPK signaling pathway might have a key role on the secondary clinical resistance, not only if they are present at diagnosis, becoming a potential target for the development of new drugs.